Join
Live feed
·
PRReleasevia Quantisnow
Tempest Therapeutics Inc. logo

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

ByQuantisnow·Wall Street's wire, on your screen.
TPST· Tempest Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TPST (Tempest Therapeutics Inc.) and more on Quantisnow.